NYSE:TEVA Teva Pharmaceutical Industries (TEVA) Stock Price, News & Analysis $34.32 +0.25 (+0.72%) Closing price 03:59 PM EasternExtended Trading$34.33 +0.01 (+0.03%) As of 06:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Teva Pharmaceutical Industries Stock (NYSE:TEVA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get TEVA alerts:Sign Up Key Stats Today's Range$34.08▼$34.5550-Day Range$28.37▼$36.3652-Week Range$14.99▼$37.35Volume6.31 million shsAverage Volume8.02 million shsMarket Capitalization$39.46 billionP/E Ratio25.80Dividend YieldN/APrice Target$41.78Consensus RatingModerate Buy Company Overview Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries. Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease. Its specialty portfolio is best known for Copaxone (glatiramer acetate), a long‑standing therapy for multiple sclerosis, while the broader business includes complex generics, emerging biosimilars, innovative formulations and pipeline programs. The company also offers contract manufacturing, licensing and distribution services and maintains R&D capabilities focused on generic product development and targeted specialty therapeutics. Headquartered in Petah Tikva, Israel, Teva has grown through a combination of organic expansion and acquisitions and serves customers across North America, Europe, Latin America, Asia Pacific and other regions. The company is overseen by a board of directors and an executive management team responsible for global operations, regulatory compliance and commercial strategy. Teva’s strategic priorities include scaling its generic offerings, advancing selected specialty programs and pursuing operational efficiencies to support its extensive international footprint.AI Generated. May Contain Errors. Read More Teva Pharmaceutical Industries Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks91st Percentile Overall ScoreTEVA MarketRank™: Teva Pharmaceutical Industries scored higher than 91% of companies evaluated by MarketBeat, and ranked 49th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingTeva Pharmaceutical Industries has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on no strong buy ratings, 9 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialTeva Pharmaceutical Industries has a consensus price target of $41.78, representing about 21.7% upside from its current price of $34.32.Amount of Analyst CoverageTeva Pharmaceutical Industries has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Teva Pharmaceutical Industries' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth22.09% Earnings GrowthEarnings for Teva Pharmaceutical Industries are expected to grow by 22.09% in the coming year, from $2.49 to $3.04 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Teva Pharmaceutical Industries is 25.80, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.53.Price to Earnings Ratio vs. SectorThe P/E ratio of Teva Pharmaceutical Industries is 25.80, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 20.73.Price to Earnings Growth RatioTeva Pharmaceutical Industries has a PEG Ratio of 3.29. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioTeva Pharmaceutical Industries has a P/B Ratio of 4.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Teva Pharmaceutical Industries' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.72% of the float of Teva Pharmaceutical Industries has been sold short.Short Interest Ratio / Days to CoverTeva Pharmaceutical Industries has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Teva Pharmaceutical Industries has recently increased by 4.72%, indicating that investor sentiment is decreasing. Dividend0.8 / 5Dividend StrengthWeak Dividend YieldTeva Pharmaceutical Industries does not currently pay a dividend.Dividend GrowthTeva Pharmaceutical Industries does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Teva Pharmaceutical Industries is 76.02%. Payout ratios above 75% are not desirable because they may not be sustainable.Dividend SustainabilityBased on earnings estimates, Teva Pharmaceutical Industries will have a dividend payout ratio of 33.26% next year. This indicates that Teva Pharmaceutical Industries will be able to sustain or increase its dividend.Read more about Teva Pharmaceutical Industries' dividend. News and Social Media4.3 / 5News Sentiment0.89 News SentimentTeva Pharmaceutical Industries has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 21 news articles for Teva Pharmaceutical Industries this week, compared to 9 articles on an average week.Search Interest28 people have searched for TEVA on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows8 people have added Teva Pharmaceutical Industries to their MarketBeat watchlist in the last 30 days. This is an increase of 167% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Teva Pharmaceutical Industries insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $42,755,980.00 in company stock.Percentage Held by Insiders0.54% of the stock of Teva Pharmaceutical Industries is held by insiders.Percentage Held by Institutions54.05% of the stock of Teva Pharmaceutical Industries is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Teva Pharmaceutical Industries' insider trading history. Receive TEVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Teva Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TEVA Stock News HeadlinesTeva TD Findings Highlight Underdiagnosis And Shape Neuroscience Growth StoryMay 20 at 11:21 AM | finance.yahoo.comTeva Pharmaceutical Industries (NYSE:TEVA) EVP Sells $5,457,268.11 in StockMay 20 at 5:35 AM | insidertrades.comNo. You’re not imagining it…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the biggest story of his 26-year career - an economic shift not seen since 1776. From the government taking stakes in Intel, Lithium Americas, and MP Materials, to sweeping political changes reshaping the economy, Stansberry argues a rare 'New 1776 Moment' is already underway. One Nobel Prize winner calls it a dividing line for all of society. His presentation covers the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.May 20 at 1:00 AM | Porter & Company (Ad)Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical OfficerMay 19 at 12:37 PM | finance.yahoo.comTeva Stock Up More Than 100% in a Year: Time to Buy, Hold or Sell?May 19 at 12:37 PM | finance.yahoo.comEliyahu Sharon Kalif Sells 153,251 Shares of Teva Pharmaceutical Industries (NYSE:TEVA) StockMay 19 at 4:01 AM | americanbankingnews.comTeva Pharmaceutical Industries (NYSE:TEVA) CAO Amir Weiss Sells 10,679 SharesMay 8, 2026 | insidertrades.comTeva Pharmaceutical Industries (NYSE:TEVA) EVP Sells 21,258 SharesMay 5, 2026 | insidertrades.comSee More Headlines TEVA Stock Analysis - Frequently Asked Questions How have TEVA shares performed this year? Teva Pharmaceutical Industries' stock was trading at $31.21 at the beginning of the year. Since then, TEVA shares have increased by 9.9% and is now trading at $34.3150. How were Teva Pharmaceutical Industries' earnings last quarter? Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced its quarterly earnings data on Tuesday, March, 31st. The company reported $0.53 earnings per share (EPS) for the quarter. The firm had revenue of $3.98 billion for the quarter. Teva Pharmaceutical Industries had a trailing twelve-month return on equity of 43.53% and a net margin of 9.01%. Read the conference call transcript. Who are Teva Pharmaceutical Industries' major shareholders? Teva Pharmaceutical Industries' top institutional investors include Harel Insurance Investments & Financial Services Ltd. (4.00%), WCM Investment Management LLC (3.55%), Rubric Capital Management LP (1.33%) and Janus Henderson Group PLC (0.42%). Insiders that own company stock include Richard D Francis, Roberto Mignone, Eliyahu Sharon Kalif, Eric A Hughes, Mark Sabag, Christine Fox, Richard Daniell, Amir Weiss, Brian Savage, Matthew Shields, Eric Drape, Placid Jover and Vikki L Conway. View institutional ownership trends. How do I buy shares of Teva Pharmaceutical Industries? Shares of TEVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Teva Pharmaceutical Industries own? Based on aggregate information from My MarketBeat watchlists, some other companies that Teva Pharmaceutical Industries investors own include NVIDIA (NVDA), Meta Platforms (META), GE Aerospace (GE), Intel (INTC), Pfizer (PFE), Advanced Micro Devices (AMD) and AT&T (T). Company Calendar Last Earnings3/31/2026Today5/20/2026Next Earnings (Estimated)7/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 TEVA's financial health is in the Green zone, according to TradeSmith. TEVA has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry MED - GENERIC DRG Sub-IndustryPharmaceutical Products Current SymbolNYSE:TEVA CIK818686 Webwww.tevapharm.com Phone(723) 914-8213Fax972-3923-4050Employees33,950Year Founded1901Price Target and Rating Average Price Target for Teva Pharmaceutical Industries$41.78 High Price Target$45.00 Low Price Target$40.00 Potential Upside/Downside+21.7%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)$1.33 Trailing P/E Ratio25.80 Forward P/E Ratio13.78 P/E Growth3.29Net Income$1.41 billion Net Margins9.01% Pretax Margin7.87% Return on Equity43.53% Return on Assets8.19% Debt Debt-to-Equity Ratio1.70 Current Ratio1.01 Quick Ratio0.78 Sales & Book Value Annual Sales$17.35 billion Price / Sales2.27 Cash Flow$3.76 per share Price / Cash Flow9.12 Book Value$7.16 per share Price / Book4.79Miscellaneous Outstanding Shares1,149,813,000Free Float1,143,604,000Market Cap$39.46 billion OptionableOptionable Beta0.86 Social Links 5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NYSE:TEVA) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredFed story no one is tellingJ.P. Morgan's Private Bank quietly advised 333 billionaire families to move 60% of their portfolios into alter...TradeSmith | SponsoredOne page of the SpaceX S-1 will move this stock overnightWhen SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including powe...Behind the Markets | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredThis same-day trade is getting a lot of attentionZero-days-to-expiration trades happen every single day - and most traders either ignore them or use them wrong...Base Camp Trading | SponsoredThe sell discipline that changed my mind after 30 yearsPorter Stansberry spent 30 years ignoring outside investment systems - until he met Emmet Savage in Dublin. Sa...Porter & Company | SponsoredMemorial Day Event: Save 79% on Weiss Ratings Plus!Elon Musk calls it 'mind-blowing.' Fox News calls the scramble for it 'the new arms race.' Chris Graebe, Chief...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Teva Pharmaceutical Industries Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Teva Pharmaceutical Industries With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
